Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.

  • 0 views
  • 02 Mar, 2022
  • 1 location
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator

enzalutamide
gilbert's syndrome
neutrophil count
rucaparib
metastatic prostate cancer
  • 14 views
  • 04 Mar, 2022
  • 2 locations
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate

  • 4 views
  • 14 Jun, 2022
  • 255 locations
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES)

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

aptt
cancer
liver metastasis
measurable disease
blood transfusion
  • 8 views
  • 27 Feb, 2022
  • 1 location
Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR)

This is a single arm, open label, phase II trial to assess efficacy of rucaparib.

prostatectomy
testosterone level
adenocarcinoma of prostate
adenocarcinoma
testosterone
  • 34 views
  • 15 Jun, 2022
  • 1 location
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.

carcinoma
maintenance therapy
carboplatin
etoposide
cancer chemotherapy
  • 1 views
  • 22 Aug, 2021
  • 1 location
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study

immunomodulators
cancer
measurable disease
EGFR
cancer chemotherapy
  • 0 views
  • 29 Sep, 2021
  • 7 locations
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

aptt
cancer
direct bilirubin
cancer of the ovary
cancer chemotherapy
  • 0 views
  • 05 Jun, 2022
  • 3 locations
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in

cancer
measurable disease
carboplatin
ct scan
growth factor
  • 8 views
  • 04 Feb, 2022
  • 3 locations
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME)

Rucaparib plus Ramucirumab with or without Nivolumab has a higher response rate than what has been reported for Ramucirumab in previously treated patients. Trial will be a phase 1/2 trial. The Phase 1

immunosuppressive agents
measurable disease
ramucirumab
growth factor
adenocarcinoma
  • 1 views
  • 22 Mar, 2022
  • 8 locations